Cost-effective Intervention for the Prevention of Cardiovascular Events There has not been much evidence on the cost-effectiveness of approved interventions for the prevention of cardiovascular
Due to our business growth, we are looking for an experienced DATA VISUALIZATION EXPERT Your task will be to make social and health economic and
Two of ESiOR’s employees, Senior Consultant Saku Väätäinen and Consultant, Market Access Manager Saara Huoponen, have completed their doctoral studies and received doctoral degrees in
We are happy to welcome Dr. Christian Asseburg – Director, Evidence Generation – and Roope Metsä – Junior Consultant! We are thrilled to have our
Register studies with excellent coverage and deep data are possible in Finland Nationwide noninterventional, retrospective chart review explored real-life characteristics and outcomes of patients with
Web-based interactive estimation app: assessment of potential incidence and cost effects related to intervention StopDia investment estimation application predicts and visualizes in simple example-type fashion
eHealth2019: Five presentations We take part in eHealth2019 – International Conference 2019 & The 24th Finnish National Conference on Telemedicine and eHealth “Data-Driven Health” in
ESiOR Oy experience is increasing… We welcome the 12th member of our team. Tuomas Lundström has joined our team as consultant and data scientist. Tuomas
Social and Health Economics and Outcomes Group (SHEOG) @LinkedIn https://www.linkedin.com/groups/8678341 You are welcome to join SHEOG! SHEOG @LinkedIn aims to encourage discussion about economic evaluation
Virtual Hospital 2.0 mid-assessment and Isaacus pre-production project results are presented as podiums in an international eHealth2018 congress ESiOR takes part in the international eHealth
ESiOR Oy gets stronger… We welcome the 10th member of our team! Namely, ISPOR-awarded Saara Huoponen has joined our team as health economic consultant and
Conditional reimbursement context: An economic evaluation including a risk-sharing scheme A hybrid-modeling study that evaluated the clinical outcomes, cost-effectiveness, and budget impact of biologic rheumatoid
